Search results for "Rosin"

showing 10 items of 831 documents

The effect of the calibre and length of needle on the stability of sclerosing foam.

2020

Objectives Little is known how calibre and length of needles affect the stability of sclerosing foam. Methods Foams were made of 0.5%, 1%, 2% and 3% polidocanol, and 0.2%, 0.5%, 1% and 3% sodium tetradecyl sulfate (STS), which were mixed with air in the proportion of 4:1. These foams were ejected through needles with the length of: 4 mm, 6 mm and 13 mm, and diameter of: 0.26 mm, 0.3 mm and 0.4 mm. Results Foams made of more concentrated polidocanol were more stable. Regarding STS an opposite relationship was revealed. Foams made of polidocanol were more stable if ejected through a longer needle, while the length of needle did not significantly affect stability of STS foams. Foams ejected th…

medicine.medical_specialtybusiness.industrySodiumPolidocanolchemistry.chemical_elementGeneral Medicine030204 cardiovascular system & hematologyGastroenterologySclerosing SolutionsPolyethylene GlycolsPolidocanolSodium Tetradecyl Sulfate030207 dermatology & venereal diseases03 medical and health sciencesFoam sclerotherapy; adverse events; needles0302 clinical medicinechemistryNeedlesInternal medicineSclerotherapymedicineHumansCardiology and Cardiovascular Medicinebusinessmedicine.drugPhlebology
researchProduct

PEST-domain-enriched tyrosine phosphatase and glucocorticoids as regulators of anaphylaxis in mice

2011

To cite this article: Obiri DD, Flink N, Maier JV, Neeb A, Maddalo D, Thiele W, Menon A, Stassen M, Kulkarni RA, Garabedian MJ, Barrios AM, Cato ACB. PEST-domain-enriched tyrosine phosphatase and glucocorticoids as regulators of anaphylaxis in mice. Allergy 2012; 67: 175–182. Abstract Background:  PEST-domain-enriched tyrosine phosphatase (PEP) is a protein tyrosine phosphatase exclusively expressed in hematopoietic cells. It is a potent negative regulator of T-cell receptor signalling that acts on receptor-coupled protein tyrosine kinases. PEST-domain-enriched tyrosine phosphatase is also expressed in mast cell and is positively regulated by glucocorticoids, but its function is unknown. In…

medicine.medical_specialtyeducationImmunologyDegranulationProtein tyrosine phosphataseBiologyImmunoglobulin EMast cellPTPN22Endocrinologymedicine.anatomical_structureInternal medicinecardiovascular systemmedicinebiology.proteinImmunology and AllergyPhosphorylationSignal transductionGlucocorticoidcirculatory and respiratory physiologymedicine.drugAllergy
researchProduct

Consensus recommendations for managing asymptomatic persistent non-virus non-alcohol related elevation of aminotransferase levels

2008

Abstract A persistent increase in non-virus non-alcohol related aminostransferase levels can have multiple causes, which differ in terms of prevalence and clinical importance. In the general population, the most frequent cause is non-alcoholic hepatic steatosis, which can evolve into steato-hepatitis and cirrhosis. The treatment for steatosis and non-alcoholic steato-hepatitis consists of modifying lifestyles, whereas the effectiveness of drug treatment remains to be determined. Other much less frequent (yet not rare) causes of persistent non-virus non-alcohol related elevations in aminotransferase levels are celiac disease and hemochromatosis, whereas autoimmune hepatitis, primary biliary …

medicine.medical_specialtyeducation.field_of_studyCirrhosisHepatologybusiness.industryPopulationGastroenterologyAutoimmune hepatitisDiseasemedicine.diseaseAsymptomaticPrimary sclerosing cholangitisPrimary biliary cirrhosisInternal medicineImmunologyEpidemiologyMedicinemedicine.symptombusinesseducationDigestive and Liver Disease
researchProduct

Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.

1994

We have analysed 118 families with inherited medullary thyroid carcinoma (MTC) for mutations of the RET proto-oncogene. These included cases of multiple endocrine neoplasia types 2A (MEN 2A) and 2B (MEN 2B) and familial MTC (FMTC). Mutations at one of 5 cysteines in the extracellular domain were found in 97% of patients with MEN 2A and 86% with FMTC but not in MEN 2B patients or normal controls. 84% of the MEN2A mutations affected codon 634. MEN 2A patients with a Cys634 to Arg substitution had a greater risk of developing parathyroid disease than those with other codon 634 mutations. Our data show a strong correlation between disease phenotype and the nature and position of the RET mutatio…

medicine.medical_specialtyendocrine system diseasesOncogene RETDNA Mutational AnalysisMolecular Sequence DataMultiple endocrine neoplasia type 2RET proto-oncogeneBiologymedicine.disease_causeProto-Oncogene MasInternal medicineProto-Oncogene ProteinsProto-OncogenesGeneticsmedicineDrosophila ProteinsHumansPoint MutationThyroid NeoplasmsMultiple endocrine neoplasiaDNA PrimersMutationBase SequencePoint mutationMultiple Endocrine NeoplasiaProto-Oncogene Proteins c-retReceptor Protein-Tyrosine KinasesExonsmedicine.diseasePhenotypeEndocrinologyPhenotypeProto-Oncogene Proteins c-retCarcinoma MedullaryCancer researchNature genetics
researchProduct

Endothelial Bmx tyrosine kinase activity is essential for myocardial hypertrophy and remodeling

2015

Cardiac hypertrophy accompanies many forms of heart disease, including ischemic disease, hypertension, heart failure, and valvular disease, and it is a strong predictor of increased cardiovascular morbidity and mortality. Deletion of bone marrow kinase in chromosome X (Bmx), an arterial nonreceptor tyrosine kinase, has been shown to inhibit cardiac hypertrophy in mice. This finding raised the possibility of therapeutic use of Bmx tyrosine kinase inhibitors, which we have addressed here by analyzing cardiac hypertrophy in gene-targeted mice deficient in Bmx tyrosine kinase activity. We found that angiotensin II (Ang II)-induced cardiac hypertrophy is significantly reduced in mice deficient i…

medicine.medical_specialtyendotheliumEndotheliumAngiogenesiscardiomyocyteCardiomegalyheartmTORC1030204 cardiovascular system & hematologyMitochondria Heart03 medical and health sciencesMice0302 clinical medicineInternal medicinemedicineAnimalsMyocytes Cardiac030304 developmental biologyMice Knockout0303 health sciencesMultidisciplinaryKinasebusiness.industryta1184Angiotensin IIBiological SciencesProtein-Tyrosine KinasesAngiotensin IImedicine.anatomical_structureEndocrinologyEtkcardiovascular systemCancer researchPhosphorylationCytokinesEndothelium VascularSignal transductionInflammation MediatorssignalingbusinessTyrosine kinaseSignal Transduction
researchProduct

Differentiation of frontal fibrosing alopecia and Lichen planopilaris on trichoscopy: A comprehensive review.

2021

Trichoscopy in dermatology has opened up the new concept in overcoming the optical challenge faced clinically. It reveals the diagnostic details to the depth of superficial dermis, and thereby increasing the clinician's diagnostic accuracy and the level of confidence. The importance of trichoscopy in cicatricial alopecia is very evident in the current scenario for its precise diagnosis. The clinical picture in delineating lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) from each other and also from other close mimickers such as androgenetic alopecia, alopecia areata, female patterned hair loss, and other cicatricial alopecia is bewildered due to its varied presentation and co…

medicine.medical_specialtyintegumentary systemAlopecia Areatabusiness.industryFrontal fibrosing alopecia610 MedizinLichen PlanusDiagnostic accuracyAlopeciaDermatologyAlopecia areatamedicine.diseaseLichen planopilarisDermatologyTrichoscopybody regionsstomatognathic diseasesCicatrixHair loss610 Medical sciencesmedicineHumansFemaleskin and connective tissue diseasesbusinessJournal of cosmetic dermatologyREFERENCES
researchProduct

Bafetinib inhibits functional responses of human eosinophils in vitro

2012

Eosinophils play a prominent role in the process of allergic inflammation. Non-receptor associated Lyn tyrosine kinases generate key initial signals in eosinophils. Bafetinib, a specific Abl/Lyn tyrosine kinase inhibitor has shown a potent antiproliferative activity in leukemic cells, but its effects on eosinophils have not been reported. Therefore, we studied the effects of bafetinib on functional and mechanistic responses of isolated human eosinophils. Bafetinib was more potent than non-specific tyrosin kinase comparators genistein and tyrphostin inhibiting superoxide anion triggered by N-formyl-Met-Leu-Phe (fMLF; 100 nM) (−log IC50=7.25±0.04 M; 6.1±0.04 M; and 6.55±0.03 M, respectively).…

medicine.medical_specialtymedicine.drug_classFarmacologíaGenisteinApoptosisPharmacologyBiologyTyrosine-kinase inhibitorAllergic inflammationchemistry.chemical_compoundCell MovementSuperoxidesLYNInternal medicinemedicineHumansProtein Kinase InhibitorsPeroxidasePharmacologyKinaseEosinophil Cationic ProteinGranulocyte-Macrophage Colony-Stimulating FactorEosinophilLeukotriene C4Respiratory burstEosinophilsN-Formylmethionine Leucyl-PhenylalaninePyrimidinesmedicine.anatomical_structureEndocrinologychemistryCalciumInterleukin-5Tyrosine kinaseEuropean Journal of Pharmacology
researchProduct

Increased nitrotyrosine plasma levels in relation to systemic markers of inflammation and myeloperoxidase in chronic heart failure

2009

The presence of a reciprocal link between inflammation and oxidative/nitrosative stress has been postulated in chronic heart failure (CHF). We aimed to determine signs of nitrosative stress in serum/plasma of CHF patients. ELISA tests were used for quantification of serum/plasma levels of Nitrotyrosine (NT), H(2)O(2), total NO, nitrite (NO(2)(-)), myeloperoxidase (MPO), Tumor Necrosis Factor-alpha (TNFalpha) and pro-Brain Natriuretic Peptide (proBNP) in 66 CHF patients (9 in NYHA I, 34 NYHA II, 23 NYHA III) and in 14 age-matched healthy subjects. NT levels were higher in NYHA III CHF patients compared to NYHA II (p<0.05), NYHA I (p<0.03) and controls (p<0.02), whereas NO(2)(-) and total NO …

medicine.medical_specialtymedicine.drug_classInflammationSystemic inflammationGastroenterologyNITROSATIVE STRESSchemistry.chemical_compoundInternal medicineBlood plasmamedicineNatriuretic peptidecardiovascular diseasesOXIDATIVE STRESSEndothelial dysfunctionbiologybusiness.industryNitrotyrosinemedicine.diseasehumanitiesEndocrinologychemistryMyeloperoxidaseHeart failureENDOTHELIAL DYSFUNCTIONcardiovascular systembiology.proteinmedicine.symptomCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiology
researchProduct

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation.

2020

Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We retrospectively evaluated how molecular monitoring has been conducted in Italy in a cohort of patients who discontinued tyrosine kinase inhibitor (TKI) treatment per clinical practice. The outcome of these patients has recently been reported&mdash

medicine.medical_specialtymedicine.drug_classlcsh:MedicineTyrosine-kinase inhibitorArticle03 medical and health sciences0302 clinical medicinechronic myeloid leukemiahemic and lymphatic diseasesInternal medicineRetrospective analysisMedicineIn patientchronic myeloid leukemia; treatment-free remission; molecular monitoringtreatment-free remissionbusiness.industrylcsh:RMyeloid leukemiaGeneral MedicineDiscontinuationmolecular monitoringchronic myeloid leukemia; molecular monitoring; treatment-free remission030220 oncology & carcinogenesisMajor Molecular ResponseCohortbusinessOff Treatment030215 immunologyJournal of clinical medicine
researchProduct

FLT3 as a therapeutic target in AML: still challenging after all these years

2010

Abstract Mutations within the FMS-like tyrosine kinase 3 (FLT3) gene on chromosome 13q12 have been detected in up to 35% of acute myeloid leukemia (AML) patients and represent one of the most frequently identified genetic alterations in AML. Over the last years, FLT3 has emerged as a promising molecular target in therapy of AML. Here, we review results of clinical trials and of correlative laboratory studies using small molecule FLT3 tyrosine kinase inhibitors (TKIs) in AML patients. We also review mechanisms of primary and secondary drug resistance to FLT3-TKI, and from the data currently available we summarize lessons learned from FLT3-TKI monotherapy. Finally, for using FLT3 as a molecul…

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentImmunologyBiologyBiochemistryTyrosine-kinase inhibitorTargeted therapychemistry.chemical_compoundfluids and secretionshemic and lymphatic diseasesInternal medicinemedicineHumansProtein Kinase InhibitorsQuizartinibHematologyMyeloid leukemiaCancerhemic and immune systemsCell BiologyHematologymedicine.diseaseLeukemia Myeloid Acutefms-Like Tyrosine Kinase 3chemistryDrug Resistance Neoplasmembryonic structuresCancer researchTyrosine kinaseCrenolanibBlood
researchProduct